Prof. Tony Mok discusses the benefits of biomarker testing for patients with lung cancer. He provides an overview of the value of genomic profiling in the first-line setting and highlights the importance of detecting resistance mutations for personalized treatments. Tony Mok is a medical oncologist and professor at the Chinese University of Hong Kong. Learn about testing for NTRK fusions: https://youtu.be/0zeO1oz6tbE?feature=shared Brought to you by Medical Affairs. Subscribe to the Illumina video channel http://www.youtube.com/subscription_center?add_user=IlluminaInc A global genomics leader, Illumina provides comprehensive next-generation sequencing solutions to the research, clinical, and applied markets. Through collaborative innovation, Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, microbiology, agriculture, forensic science, and beyond. View customer spotlight videos https://www.youtube.com/playlist?list=PLKRu7cmBQlajfheLzgbI4S7xBn7IDbt79 View Illumina webinars https://www.youtube.com/playlist?list=PLKRu7cmBQlahpXlnrrXlQw9itVJ8yHwUZ View Illumina support videos https://www.youtube.com/playlist?list=PLKRu7cmBQlajbm2KGsICWb-JOnusJfYvM Facebook: https://www.facebook.com/illuminainc LinkedIn: https://www.linkedin.com/company/illu... Instagram: https://www.instagram.com/illuminainc/ Twitter: https://twitter.com/illumina